Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 108, Issue 42, Pages 17468-17473
Publisher
Proceedings of the National Academy of Sciences
Online
2011-10-11
DOI
10.1073/pnas.1111138108
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The bone marrow microenvironment as a sanctuary for minimal residual disease in CML
- (2010) Rajesh R. Nair et al. BIOCHEMICAL PHARMACOLOGY
- Galectin-3: A novel substrate for c-Abl kinase
- (2010) Vitaly Balan et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death
- (2010) M. J. Streetly et al. BLOOD
- Wnt/Ca2+/NFAT Signaling Maintains Survival of Ph+ Leukemia Cells upon Inhibition of Bcr-Abl
- (2010) Mark A. Gregory et al. CANCER CELL
- Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment
- (2010) M Takeuchi et al. CELL DEATH AND DIFFERENTIATION
- c-Abl and Arg tyrosine kinases regulate lysosomal degradation of the oncoprotein Galectin-3
- (2010) X Li et al. CELL DEATH AND DIFFERENTIATION
- Emerging drugs for chronic myeloid leukemia
- (2010) Daniela Cilloni et al. EXPERT OPINION ON EMERGING DRUGS
- Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis
- (2010) F. Vianello et al. HAEMATOLOGICA
- Chronic myeloid leukemia: mechanisms of blastic transformation
- (2010) Danilo Perrotti et al. JOURNAL OF CLINICAL INVESTIGATION
- Advances in treatment of chronic myelogenous leukemia – new treatment options with tyrosine kinase inhibitors
- (2010) Fabio P. S. Santos et al. LEUKEMIA & LYMPHOMA
- Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
- (2010) Douglas W McMillin et al. NATURE MEDICINE
- Resistance to Imatinib: Mutations and Beyond
- (2010) Paul La Rosée et al. SEMINARS IN HEMATOLOGY
- Increased Serum 90K and Galectin-3 Expression Are Associated with Advanced Stage and a Worse Prognosis in Diffuse Large B-Cell Lymphomas
- (2009) Seok Jin Kim et al. ACTA HAEMATOLOGICA
- Regulation of Prostate Cancer Progression by Galectin-3
- (2009) Yi Wang et al. AMERICAN JOURNAL OF PATHOLOGY
- Advances in the biology and therapy of patients with chronic myeloid leukaemia
- (2009) Elias Jabbour et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia
- (2009) D. Milojkovic et al. CLINICAL CANCER RESEARCH
- Osteoclasts are involved in the maintenance of dormant leukemic cells
- (2009) Asumi Yokota et al. LEUKEMIA RESEARCH
- Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance
- (2009) D. Bixby et al. Hematology-American Society of Hematology Education Program
- AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance
- (2008) K. Balakrishnan et al. BLOOD
- Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis
- (2008) Neil P. Shah et al. CANCER CELL
- Involvement of BH3-only proteins in hematologic malignancies
- (2008) Junya Kuroda et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
- (2008) J A McCubrey et al. LEUKEMIA
- Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
- (2008) E. Weisberg et al. MOLECULAR CANCER THERAPEUTICS
- Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells
- (2008) Angela Colmone et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started